




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Latest in Cardiology</title>
        <link>http://www.acc.org/Feed/LatestCardiology?topicID=8d7f3960-0beb-4a23-b87d-661262d0bb4f</link>
        <description>ACC Feed: Latest in Cardiology</description>
        <language>en</language>

        


                <item>
                    <title>ACC Practice Made Perfect: The Future of Cardiovascular Leadership - Innovation and Value-Based Care</title>
<link>/Latest-in-Cardiology/Articles/2026/05/08/13/44/PMP_08may2026</link>                    <description>In this episode, sponsored by the CV Management Section, we look ahead at the forces shaping the future of cardiovascular leadership.</description>
                    <pubdate>1778247960000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>AI-Enabled Clinician: Patient Engagement and Care Transformation with AI-Quantified Plaque Analysis</title>
<link>/Latest-in-Cardiology/Articles/2026/05/07/15/36/ai-enabled-clinician-07may2026</link>                    <description>In this episode, Chief Innovation Officer, Ami Bhatt, MD, FACC and Allen Taylor, MD, FACC discuss the importance of cardiovascular prevention and early screening through AI-quantified plaque analysis by drawing parallels to how oncology and gastroenterology approach early detection.</description>
                    <pubdate>1778168340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>New in Clinical Guidance | Key Points From the 2026 Advanced Training Statement on CCEP</title>
<link>/Latest-in-Cardiology/Articles/2026/06/01/01/New-in-Clinical-Guidance-2026-ATS-CCEP</link>                    <description>The following are key points from the 2026 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (Revision of the 2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology)...</description>
                    <pubdate>1778156160000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Rhythm Control May Improve Moderate-Severe/Severe Secondary TR</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/05/04/11/24/Rhythm-Control-May-Improve</link>                    <description>Successful rhythm control of atrial fibrillation (AFib) was associated with improved secondary tricuspid regurgitation (STR) in patients with moderate-severe or severe STR, according to research published April 23 in JACC: Cardiovascular Imaging.</description>
                    <pubdate>1778094060000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Poor Visual Acuity Associated With Cardiovascular, All-Cause Mortality Risk</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/05/04/11/24/Poor-Visual-Acuity</link>                    <description>In a nationwide cohort of more than 2.5 million Chinese adults aged 65 years or older, visual acuity (VA) impairment was highly prevalent and independently associated with increased risk of mortality from any cause and from cardiovascular disease, according to a large-scale study published April 15 in JACC.</description>
                    <pubdate>1778087340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Hypertension Risk From Low-Level PM Exposure</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/05/04/11/24/Hypertension-Risk-From-Low-Level-PM-Exposure</link>                    <description>Long-term exposure to fine particulate matter &#226;‰&#164;2.5 &amp;mu;m in diameter (PM2.5), which is below current regulatory thresholds in the U.S., may contribute to increased hypertension risk, according to a national cohort study published April 15 in JACC.</description>
                    <pubdate>1778087340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ORBITA Analysis: Microvascular Resistance Impacts PCI Benefit</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/05/04/11/24/ORBITA-Analysis</link>                    <description>Patients with lower microvascular resistance (MVR) saw greater placebo-controlled benefit from PCI, according to a retrospective analysis of the ORBITA trial published April 29 in JACC: Cardiovascular Interventions.</description>
                    <pubdate>1778087340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>BP Reduction Brings Comparable CV Benefits in CKD</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/05/04/11/24/BP-Reduction</link>                    <description>Patients with chronic kidney disease (CKD) enjoyed the same reduction in cardiovascular risk from lowering systolic blood pressure (SBP) as those without CKD, and this finding held across all CKD stages, BP thresholds, proteinuria status and antihypertensive class, according to research published April 25 in The Lancet.</description>
                    <pubdate>1778087340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>CARES Data: Odds of Positive OHCA Outcomes Worsen at Night</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/05/04/11/24/CARES-Data</link>                    <description>Nighttime response for out-of-hospital cardiac arrest (OHCA) was associated with lower odds of sustained return of spontaneous circulation (ROSC), neurologically favorable survival (Cerebral Performance Category of 1 or 2) and postresuscitation survival compared to daytime, even after adjusting for patient and event characteristics...</description>
                    <pubdate>1778087340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>FDA Update: Agency Authorizes Sale of Fruit Flavored Glas E-Cigarettes</title>
<link>/Latest-in-Cardiology/Articles/2026/05/06/16/56/FDA-Update-Agency-Authorizes-Sale-of-Fruit-Flavored-Glas-E-Cigarettes</link>                    <description>The U.S. Food and Drug Administration (FDA) has taken an unprecedented step by authorizing the marketing of four Glas e-cigarettes, including the following pod flavors: Classic Menthol, Fresh Menthol, Gold (mango flavored) and Sapphire (blueberry flavor).</description>
                    <pubdate>1778086620000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>